




# Valproic acid (sodium valproate)

Statut de médicament essentiel 

Section: 5. Medicines for diseases of the nervous system > 5.1. Antiseizure medicines

EMLc

Codes ATC: N03AG01

|                              |  |
|------------------------------|--|
| Indication                   | Status epilepticus <span>Code ICD11: 8A66</span>   |
| INN                          | Valproic acid  |
| Type de médicament           | Chemical agent   |
| Type de liste                | Liste complémentaire (EML) (EMLc)  |
| Additional notes             | Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb. |
| Formulations                 | Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule ; 100 mg per mL in 10 mL ampoule ; 100 mg per mL in 3 mL ampoule   |
| Historique des statuts LME   | Ajouté pour la première fois en 2015 (TRS 994)<br>Modifié en 2021 (TRS 1035)<br>Modifié en 2023 (TRS 1049)   |
| Sexe                         | Tous   |
| Âge                          | Aussi recommandé pour les enfants  |
| Équivalence thérapeutique    | La recommandation concerne ce médicament spécifique  |
| Renseignements sur le brevet | Patents have expired in most jurisdictions<br>Lire la suite <a href="#">sur les brevets.</a>    |
| Wikipédia                    | <a href="#">Valproic acid (sodium valproate)</a>    |
| DrugBank                     | <a href="#">Valproic acid</a>   |

## Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional vial size of valproic acid injection (100 mg/mL in 3 mL) on the EML and EMLc.

